If there was one clear signal in today’s funding landscape, it was that venture investors are no longer paying simply for “AI exposure.” They are paying for control points: endpoint security, military cyber operations, healthcare billing infrastructure, drug programs, industrial fabrication, and cell-therapy platforms that can plausibly compress timelines or widen margins in markets that already spend heavily. The biggest checks of the day went to companies sitting close to budget owners, regulated workflows, or procurement systems that are hard to rip out once embedded.
The second notable theme is how broad the definition of “AI startup” has become. Glow is using AI to rethink endpoint security. Candid Health is applying automation and AI agents to revenue cycle management. StrongestLayer is pushing reasoning-based email security. 1872 is translating physical AI into steel fabrication. Passionfroot is betting that, as software becomes easier to build, distribution and human trust become scarcer assets. That is not a consumer-AI story. It is an operating-system story for industries that already have money at stake.
There was also a pronounced barbell shape to the day. On one side sat large, conviction rounds for companies already operating with late-stage, enterprise, or strategically sensitive profiles, including Glow, Cathedral, Crystalys Therapeutics, and Candid Health. On the other side sat smaller but targeted financings in biotech and applied software, where investors appear willing to fund narrow technical wedges so long as the science, workflow, or data advantage is specific enough. That mix says a lot about today’s market: bold checks still happen, but they are increasingly reserved for companies that look less like experiments and more like future infrastructure.
The Macro Environment: Capital Is Chasing Control Points
The strongest pattern across today’s rounds is that investors are backing companies that can own a mission-critical workflow instead of selling a thin feature. Glow wants to sit between enterprise devices and the software, agents, and packages employees can install. Candid Health wants to become the financial system of record for provider billing. StrongestLayer wants to judge email intent rather than add yet another filter. Passionfroot is trying to become the execution layer for creator-led B2B demand generation. Each of those is a bet that the durable value in AI will sit in system orchestration, not in the model layer alone.
Investor psychology also looks more concentrated. Sequoia showed up on Glow and Cathedral. Insight Partners led Passionfroot. Sixth Street Growth led Candid Health. Frazier Life Sciences led Crystalys. Menlo-backed seed financings like Cheiron did not make today’s final top ten, while capital poured toward companies with either strong specialist investors or investors capable of supporting later rounds and enterprise scale. That matters because this market is increasingly rewarding syndicate quality as a signal of survivability, not just price.
Biotech financing, meanwhile, continues to split into two very different buckets. Late-stage or clinically de-risked assets such as Crystalys can still raise large, oversubscribed rounds with crossover-style support because their path to value creation is legible. Earlier-stage companies like Tikva Allocell, Brenus Pharma, and Immitra Bio are still getting funded, but with much tighter narratives: one lead candidate, one technical advantage, one near-term milestone. Capital is available, but it is more disciplined and less forgiving of vague “platform” stories than it was in the broad biotech boom years.
Geographically, the United States still dominated the largest checks, but Europe was hardly quiet. Berlin, London, Lyon, and Zürich all produced financings that matter for how investors are thinking about distribution software, energy analytics, immunotherapy, and gene editing. The difference was not just size. It was emphasis. Europe’s rounds skewed toward capital-efficient specialist companies, while the U.S. produced the day’s largest financings in cyber, healthcare infrastructure, and defense-adjacent software.
The 10 Venture Funding Deals
Glow raises $180 million in funding to challenge endpoint security in the AI era
Glow’s emergence from stealth at a $1.2 billion valuation is one of the day’s clearest signals that cybersecurity remains one of venture’s highest-conviction categories. The company is building endpoint security software designed for a world where employees run AI agents, install new developer tools quickly, and increasingly introduce risk before a security team can react. Investors including Sequoia Capital, Cyberstarts, Greenoaks, Redpoint Ventures, Index Ventures, Lux Capital, and others are effectively betting that the endpoint becomes even more important as AI shifts decision-making and code execution closer to individual devices.
Why investors care is straightforward: the endpoint is where AI adoption turns into enterprise risk. Cloud security has already produced giants, but the AI era is creating a fresh attack surface around local software, package installs, and agent activity. Glow’s thesis is that prevention at the endpoint can become a bigger market now that enterprises are wrestling with new kinds of software autonomy. The competitive set is formidable, with CrowdStrike, Microsoft, SentinelOne, and Palo Alto Networks already entrenched, but Glow is not trying to win by being another detection layer. It is trying to become the policy and orchestration layer that decides what software and agents should be allowed into the environment in the first place. That is a larger ambition, and the size of the round reflects it.
The valuation matters too. A $1.2 billion Series A is a statement that top-tier investors still believe large cyber outcomes can be built quickly when the founding team is credible, and the platform is positioned close to a new category transition. Former Meta and Snowflake executives, plus a leadership team with direct exposure to Wiz’s rise, gave investors enough confidence to underwrite scale before revenue metrics were publicly disclosed. That is unusual, but not irrational in a category where speed can shape market structure.
Funding Details Startup: Glow Investors: Sequoia Capital, Cyberstarts, Greenoaks, Redpoint Ventures, Index Ventures, Swish Ventures, Lux Capital, Operator Collective, Holly Ventures Amount Raised: $180 million Total Raised: $180 million disclosed Funding Stage: Series A Funding Date: July 22, 2026 Headquarters: Palo Alto, California, United States Sector: Cybersecurity
Cathedral raises $160M in funding to build AI-driven military cyber operations
Cathedral is the day’s most politically charged and geopolitically consequential round. Reuters reported that the company, launched by former Department of Government Efficiency staffers, closed a $160 million financing at a $1.4 billion valuation, led by Andreessen Horowitz and Sequoia Capital. The startup aims to expand U.S. military cyber capabilities using AI, including offensive and defensive operations, and is reportedly exploring dedicated compute capacity through a data-center acquisition or partnership.
Why this matters goes beyond the size of the check. Defense-tech funding has been growing for years, but Cathedral sits at the intersection of three forces that now have serious venture backing: AI-enabled national security software, direct founder ties to federal procurement circles, and investor belief that geopolitical competition justifies unusually aggressive underwriting. This is not a generic “AI for government” company. It is a bet that cyber offense, cyber defense, and compute ownership are becoming tightly linked national capabilities.
The strategic implication for founders is that the defense-tech window is widening, but only for teams that can sell into real programs of record or meaningfully shorten government decision cycles. Cathedral may benefit from proximity to power, but that also creates execution and scrutiny risk. The same government ties that can accelerate contracts can also invite political backlash and expose the company if the political winds shift. Investors clearly think the upside outweighs that risk.
Funding Details Startup: Cathedral Investors: Andreessen Horowitz, Sequoia Capital Amount Raised: $160 million Total Raised: $160 million publicly disclosed Funding Stage: Not publicly disclosed Funding Date: July 22, 2026 Headquarters: Not publicly disclosed Sector: Defense tech and cybersecurity
Crystalys Therapeutics raises $130M to push late-stage gout program toward commercialization
Crystalys Therapeutics landed one of the largest healthcare rounds of the day with a $130 million Series B to support Phase Three development and commercialization prep for dotinurad, a once-daily oral URAT1 inhibitor for gout. Frazier Life Sciences led, with participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, KCap Biotechnology Fund, and all existing investors. The financing was described as oversubscribed, which is worth noting in a biotech market that has often favored only the cleanest late-stage stories.
Investors care here because Crystalys is far past the “science project” phase. The company already launched from stealth with a $205M Series A last September and is now using new capital to advance an asset already in global late-stage studies. That makes this round less about speculative platform optionality and more about underwriting commercial probability. In a market that has become skeptical of open-ended biotech narratives, that distinction is everything.
This round also reinforces a broader truth about biotech financing in 2026: when a company can show a credible registration path and a clear unmet-need market, it can still draw heavyweight capital. The flip side is that investors are concentrating money into fewer, later, better-defined stories. Crystalys fits that mold almost perfectly.
Funding Details Startup: Crystalys Therapeutics Investors: Frazier Life Sciences, Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, KCap Biotechnology Fund, and existing investors including Novo Holdings and SR One Amount Raised: $130 million Total Raised: $335 million Funding Stage: Series B Funding Date: July 22, 2026 Headquarters: San Diego, California, United States Sector: Biotech
Candid Health raises $120M in funding to automate healthcare revenue cycle management
Candid Health’s Series D might be the best example today of where software investors still see room for breakout returns in healthcare. The company raised $120 million led by Sixth Street Growth, with participation from Oak HC/FT, 8VC, and Y Combinator. Candid says it is building autonomous revenue cycle management for healthcare providers, targeting a part of the U.S. system that burns roughly $280 billion a year. Its latest round triples its valuation versus the February 2025 Series C, while the company reports 190% year-over-year annual contracted run-rate revenue growth and 180% net dollar retention in 2025.
Investors are not backing Candid because medical billing is glamorous. They are backing it because healthcare billing is messy, expensive, recurring, and deeply tied to operating cash flow. That makes it exactly the sort of category where AI can matter, assuming the product is embedded deeply enough to change workflows rather than merely summarize them. Candid’s pitch is that legacy systems cannot handle provider complexity, and that incremental AI layered on top does not solve the root problem. The company is instead trying to own the underlying infrastructure.
This round is also a reminder that “AI in healthcare” increasingly means back-office productivity, reimbursement, and financial plumbing, not only diagnostics or clinical decision support. That may disappoint some founders who want splashier narratives, but it is often where the spend is clearer, and adoption friction is lower. Investors appear to understand that.
Funding Details Startup: Candid Health Investors: Sixth Street Growth, Oak HC/FT, 8VC, Y Combinator Amount Raised: $120 million Total Raised: $219.5 million Funding Stage: Series D Funding Date: July 22, 2026 Headquarters: San Francisco, California, United States Sector: Healthcare infrastructure and enterprise software
Passionfroot raises $15 million in funding to turn creator-led growth into B2B infrastructure
Passionfroot’s $15 million Series A, led by Insight Partners with participation from Creandum, Supernode Global, and s16vc, is one of the more interesting “second-order AI” deals of the day. The Berlin company is building a marketplace and workflow layer connecting B2B creators with brands. On the surface, that can sound like marketing software. Underneath, it is a bet that AI is making product creation cheaper and category noise louder, which in turn makes distribution and trusted human narrative more valuable.
That framing matters. Passionfroot’s customers include AI-native companies such as ElevenLabs, Figma, Replit, Framer, and Gamma, and the startup says revenue grew thirteen-fold over the past year while remaining profitable with a team of fifteen. Investors are not just funding a marketplace. They are funding a workflow system for a new form of B2B go-to-market, one where independent experts, newsletter writers, podcasters, and builders become a purchase channel. That smells less like ad tech and more like infrastructure for modern software distribution.
For founders, the larger lesson is clear: when AI compresses product differentiation, distribution becomes a moat again. Passionfroot is building straight into that shift, which helps explain why Insight was willing to lead at this stage.
Funding Details Startup: Passionfroot Investors: Insight Partners, Creandum, Supernode Global, s16vc Amount Raised: $15 million Total Raised: More than $21 million Funding Stage: Series A Funding Date: July 22, 2026 Headquarters: Berlin, Germany Sector: Enterprise software and go-to-market infrastructure
1872 raises $15 million in funding to automate steel fabrication with physical AI
1872 may not be the biggest round of the day, but it is one of the clearest examples of physical AI moving from pitch deck to factory floor. The company, founded by three former SpaceX engineers, launched with a $15 million seed round led by The O.H.I.O. Fund to build an autonomous steel fabrication factory model in Cincinnati. Its software is designed to coordinate procurement, production planning, robotics, machine control, and shop-floor movement for heavy steel fabrication.
Investors care because steel fabrication is a painful category to automate: labor shortages are real, welding remains difficult to automate at scale, and lead times are long. If 1872 can reduce delivery timelines from months to weeks, it is not just selling software. It is remapping industrial throughput. The partnership with Path Robotics strengthens that thesis by giving 1872 a serious robotics counterpart rather than forcing it to build every layer itself.
This is the sort of deal founders in industrial tech should study. The company is not pitching a generic “AI for manufacturing” idea. It has picked a constrained but economically large wedge, tied it to labor shortages and infrastructure demand, and located the business inside a region that wants advanced manufacturing to return. That is a much stronger story than broad industrial automation rhetoric.
Funding Details Startup: 1872 Investors: The O.H.I.O. Fund Amount Raised: $15 million Total Raised: $15 million disclosed Funding Stage: Seed Funding Date: July 22, 2026 Headquarters: Cincinnati, Ohio, United States Sector: Industrial automation and manufacturing software
Brenus Pharma raises €11 million in funding to advance immunotherapy for hard-to-treat solid tumors
Brenus Pharma raised € 11 million in a Series A extension, bringing total capital raised since inception to € 38 million. The extension drew follow-on support from existing investors such as Angelor, UI Investissement, Crédit Agricole vehicles, Noshaq, Orsa, BIO JAG, and Bpifrance, while also bringing in Sambrinvest and Korea Omega Investment Corp. That mix of existing support plus new international capital is exactly what founders want to see in a clinical-stage biotech extension: insiders are still writing checks, and outsiders believe the next inflection point is worth entering for.
The company’s appeal rests on its attempt to make “cold” solid tumors visible to the immune system using an off-the-shelf platform rather than a heavily personalized manufacturing model. Whether Brenus ultimately succeeds is a clinical question, but investors are clearly buying the economic logic as well as the biology. Manufacturing simplicity and predictable supply are not side notes in modern oncology. They are part of the product.
This is also a useful example of how European biotech rounds are being financed now. The round is not enormous by U.S. late-stage standards, but it is large enough to carry a defined program through a meaningful milestone, in this case advancing STC-1010 through Phase One. That is how disciplined biotech capital tends to behave when sentiment is selective rather than euphoric.
Funding Details Startup: Brenus Pharma Investors: Angelor, UI Investissement, Crédit Agricole affiliates, Noshaq, Orsa, BIO JAG, Bpifrance, Sambrinvest, Korea Omega Investment Corp. Amount Raised: €11 million Total Raised: €38 million Funding Stage: Series A extension Funding Date: July 22, 2026 Headquarters: Lyon, France Sector: Biotech
Tikva Allocell raises $8 million to move an off-the-shelf solid-tumor cell therapy toward the clinic
Tikva Allocell closed an $8 million Series A led by Kantharos Capital to fund IND-enabling work and a planned year-end IND submission for TAVST01, its lead allogeneic cell-therapy candidate for B7-H3-positive solid tumors. The Singapore company is building on EBV-specific T cells designed to persist longer and better resist immune rejection, one of the central technical obstacles that has limited allogeneic approaches in solid tumors.
Why investors care is that the company is not merely proposing another platform story in cell therapy. It is addressing a known failure point with a specific biological angle and a concrete regulatory milestone. That is exactly the sort of early-stage biotech proposition that can still get funded even when the broader market is cautious. The round is modest, but it is enough to test whether the technical premise survives contact with regulators and early clinical development.
For founders in biotech, Tikva is a reminder that small rounds can still be strategically meaningful when they fund one milestone that materially changes a company’s value. In this market, that kind of precision can be a feature rather than a limitation.
Funding Details Startup: Tikva Allocell Investors: Kantharos Capital Amount Raised: $8 million Total Raised: $8 million publicly disclosed Funding Stage: Series A Funding Date: July 22, 2026 Headquarters: Singapore Sector: Biotech
StrongestLayer raises $4.1 million in funding to defend inboxes against reasoning-based attacks
StrongestLayer announced $4.1 million in new funding, bringing total seed funding to $9.3 million. Inovia Capital led the new round, with participation from Sorenson Capital, LaunchPod, Alumni Ventures, and former Mandiant chief product officer Chris Key. The company argues that a growing share of damaging email attacks now evade traditional pattern-matching systems, especially scams and business-email-compromise attempts that contain no obviously malicious payload.
This round matters less because of its size and more because of its product thesis. Security buyers are increasingly open to replacing or supplementing “AI-washed” point products if a new entrant can show materially better performance against fast-changing attack types. StrongestLayer is betting that reasoning about message intent will matter more than signatures, reputation databases, or historical behavior. That is a serious claim, but it is also the direction many defenders think the market is heading.
The investor commentary is telling too. Inovia’s view was not merely that the company is interesting; it was that StrongestLayer achieved incumbent-displacing capability with limited capital. That is exactly the kind of efficiency argument that carries weight in a venture market where investors still want upside but no longer want to subsidize bloated burn by default.
Funding Details Startup: StrongestLayer Investors: Inovia Capital, Sorenson Capital, LaunchPod, Alumni Ventures, Chris Key Amount Raised: $4.1 million Total Raised: $9.3 million Funding Stage: Seed extension Funding Date: July 22, 2026 Headquarters: San Francisco, California, United States Sector: Cybersecurity
Immitra Bio raises €2.58 million in funding to make in-vivo gene editing more scalable
Immitra Bio closed an upsized two-point-five-eight-million-euro pre-seed round led by Backbone Ventures and co-led by OCCIDENT, with participation from Another VC, Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT, ETH Foundation, and private investors. The Zürich company is trying to build mutation-agnostic, in-vivo gene-editing therapies that can avoid the manufacturing burden and toxicity associated with ex-vivo approaches.
The round is small in absolute terms, but strategically important because it funds one of the most attractive long-term ideas in biotech: turning gene editing into something more scalable, less personalized, and therapeutically broader. Investors are not paying for commercial readiness here. They are paying for a credible early technical wedge in a market where successful platform shifts can create enormous optionality downstream.
Immitra’s financing also shows how pre-seed life-science rounds are being built in Europe now. Rather than one giant check from a single fund, the round is assembled from specialist early-stage investors, non-dilutive support, and institution-adjacent backers who can help the company prove enough science to become financeable at the next stage.
Funding Details Startup: Immitra Bio Investors: Backbone Ventures, OCCIDENT, Another VC, Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT, ETH Foundation, private investors Amount Raised: €2.58 million Total Raised: €2.58 million disclosed Funding Stage: Pre-seed Funding Date: July 22, 2026 Headquarters: Zürich, Switzerland Sector: Biotech and gene editing
What Today’s Funding Activity Reveals
The first pattern is concentration around software that can sit directly on top of spend. Cybersecurity, billing, industrial production, and defense are not “nice to have” budgets. They are pressured budgets. That helps explain why Glow, Cathedral, Candid Health, 1872, and StrongestLayer all found financing on the same day despite serving very different buyers. The common thread is operational urgency.
The second pattern is that AI is being financed as an execution layer, not only as a model layer. Investors funded companies that reason about malicious emails, orchestrate reimbursement workflows, coordinate steel fabrication, and manage creator-led distribution. Even when the company is not selling a foundation model, AI is increasingly the mechanism that lets a startup attack a workflow that incumbents treated as too messy to automate.
The third pattern is selective appetite for biotech. Capital is still available, but there is a sharp divide between late-stage, commercial-path stories like Crystalys and earlier scientific gambles like Tikva, Brenus, and Immitra. Investors still fund both ends of that continuum, but the narrative discipline has tightened. The company has to show either line of sight to approval or a very specific technical inflection point. Generalized “platform optionality” is no longer enough on its own.
Finally, geography mattered less than category fit. The largest dollars still went to U.S. companies, but Europe produced meaningful financings in biotech and software infrastructure. That suggests the market is not short on ideas; it is short on patience for weak wedges. Where a company is based matters less than whether it owns a defensible control point in a market buyers already understand.
Venture Funding Table
Startup Amount Raised Sector Funding Stage Lead Investors Country Glow $180M Cybersecurity Series A Sequoia Capital, Cyberstarts United States Cathedral $160M Defense tech and cybersecurity Not publicly disclosed Andreessen Horowitz, Sequoia Capital Not publicly disclosed Crystalys Therapeutics $130M Biotech Series B Frazier Life Sciences United States Candid Health $120M Healthcare infrastructure Series D Sixth Street Growth United States Passionfroot $15M Enterprise software Series A Insight Partners Germany 1872 $15M Industrial automation Seed The O.H.I.O. Fund United States Brenus Pharma €11M Biotech Series A extension Follow-on syndicate plus Sambrinvest and Korea Omega Investment Corp. France Tikva Allocell $8M Biotech Series A Kantharos Capital Singapore StrongestLayer $4.1M Cybersecurity Seed extension Inovia Capital United States Immitra Bio €2.58M Biotech and gene editing Pre-seed Backbone Ventures, OCCIDENT SwitzerlandStrategic Takeaways for Founders and Investors
Founders should notice what did and did not get funded today. The winners were not selling abstract AI promise. They were attached to a painful workflow, a regulated pathway, a procurement engine, or a capital allocation problem. If you are building in software, the better narrative now is not “we use AI,” but “we remove labor, leakage, delay, or risk in a line item the customer already budgets for.” Glow, Candid Health, 1872, and StrongestLayer all fit that mold in different ways.
Investors, meanwhile, are prioritizing defensibility that survives AI commoditization. Passionfroot’s argument is that distribution moats matter more when software creation gets cheaper. Glow’s argument is that endpoint control matters more when AI agents proliferate. Candid’s argument is that a systems-level position in billing matters more than a narrow AI feature. These are all variations on the same portfolio logic: if intelligence becomes abundant, the scarce asset is control over execution, trust, and workflow context.
Capital efficiency still matters below the very top tier. Passionfroot says it stayed profitable while growing fast with a team of fifteen. StrongestLayer raised a relatively small extension while claiming major product displacement. Immitra and Tikva raised targeted rounds built around specific proof points. Even in a market that still writes nine-figure checks, there is a strong preference for founders who can explain exactly what the next dollar buys.
The practical takeaway is that timing favors founders who can show one of three things: immediate economic ROI, a credible path into a strategic procurement budget, or a sharply defined milestone that changes financing risk. Everyone else is still fundraising into a market that is open, but far less forgiving than the old growth-at-any-price era.
Conclusion
Taken together, today’s rounds point to a startup market that is becoming tougher, narrower, and more interesting all at once. Tougher, because investors are concentrating dollars into fewer stories with clearer ownership of a budget, a workflow, or a milestone. Narrower, because generic software and vague platform claims are struggling to command the same enthusiasm. More interesting, because the companies still getting funded are often building in places where software directly touches industrial output, healthcare cash flow, national security, or the economics of scientific development.
That is where the ecosystem appears to be heading: away from broad thematic optimism and toward precision. Venture capital is still willing to move fast and write very large checks. But increasingly, it wants proof that a startup can become infrastructure for a decisive part of the economy, not just another participant in it.
